Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in Korea

Yonsei University

Status: Unknown

Conditions: Atrophic Gastritis

Treatments: Drug: pepsinogen and gastrin

Study type: Observational

Funder types: Other

Identifiers

NCT02184910

4-2013-0722

Details and patient eligibility

About

It is well-known that atrophic gastritis is a major risk factor for gastric cancer, which leads to variations in the serum levels of gastrin, pepsinogen (PG) I, and PGII. We want to assess the effects of age, sex, and Helicobacter pylori status on pepsinogen (PG) level for atrophic gastritis and whether gastric atrophy based on the PG test would be improved after H. pylori eradication.

Enrollment: 108 estimated patients

Sex: Female

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. over 19 years
2. the patients who have gastrointestinal discomfort or get esophagogastroduodenoscopy (EGD) for health check up
3. the patients who got the procedure, endoscopic submucosal resection (ESD) for early gastric cancer

Exclusion criteria

1. gastrectomy history
2. advanced gastric cancer (impossible to get the gastrectomy)
3. Helicobacter eradication history
4. the patients who have chronic disease
5. cancer patients except gastric cancer within 6 months
6. who cannot perform this study according to research's decision
7. who have bleeding tendency (ex. taking antiplatelet agent, low platelet count or abnormal coagulation time)

Trial design

108 participants in 1 patient group

gastritis and pepsinogen

Treatment:

Drug: pepsinogen and gastrin